Literature DB >> 16582636

The dual specificity phosphatase Cdc25C is a direct target for transcriptional repression by the tumor suppressor p53.

Selvon St Clair1, James J Manfredi.   

Abstract

The cdc25C gene has been shown to be a novel target for transcriptional downregulation by p53. Two independent mechanisms contribute to the p53-dependent repression of the cdc25C gene. First, an element in the cdc25C promoter consisting of a binding site for p53 plus an adjacent 8 base pairs confers p53-dependent repression. Mutation of either the p53 binding site or the adjacent 8 bp sequence abolishes this effect. The element conferring p53-dependent repression also contains a binding site for the transcription factor Sp1 and a mutant p53 protein that retains the ability to interact with the p53-binding site is defective in mediating repression. Second, a minimal promoter lacking the p53 binding site but containing a previously characterized CDE/CHR element is also repressed by p53. This repression is abrogated when a 5 bp mutation is introduced in the CHR sequence. These results support a model for p53 downregulating cdc25C expression, in part, by direct binding to a promoter element that is likely to require cooperation with an additional cellular factor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16582636     DOI: 10.4161/cc.5.7.2628

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  15 in total

1.  Identification and modeling of a phosphatase-like domain in a tRNA 2'-O-ribosyl phosphate transferase Rit1p.

Authors:  Anna Czerwoniec; Janusz M Bujnicki
Journal:  Cell Cycle       Date:  2011-10-15       Impact factor: 4.534

2.  Endothelial cell responses to atheroprone flow are driven by two separate flow components: low time-average shear stress and fluid flow reversal.

Authors:  Daniel E Conway; Marcie R Williams; Suzanne G Eskin; Larry V McIntire
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-11-13       Impact factor: 4.733

3.  Mdm2 promotes Cdc25C protein degradation and delays cell cycle progression through the G2/M phase.

Authors:  L E Giono; L Resnick-Silverman; L A Carvajal; S St Clair; J J Manfredi
Journal:  Oncogene       Date:  2017-08-14       Impact factor: 9.867

4.  The Levels of H11/HspB8 DNA methylation in human melanoma tissues and xenografts are a critical molecular marker for 5-Aza-2'-deoxycytidine therapy.

Authors:  Cynthia C Smith; Baiquan Li; Juan Liu; Kie-Sok Lee; Laure Aurelian
Journal:  Cancer Invest       Date:  2011-07       Impact factor: 2.176

5.  Methylation by NSun2 represses the levels and function of microRNA 125b.

Authors:  Shuai Yuan; Hao Tang; Junyue Xing; Xiuqin Fan; Xiaoyu Cai; Qiu Li; Pei Han; Yuhong Luo; Zhuojun Zhang; Bin Jiang; Yali Dou; Myriam Gorospe; Wengong Wang
Journal:  Mol Cell Biol       Date:  2014-07-21       Impact factor: 4.272

6.  p53-dependent repression of polo-like kinase-1 (PLK1).

Authors:  Lynsey McKenzie; Sharon King; Lynnette Marcar; Sam Nicol; Sylvia S Dias; Katie Schumm; Pamela Robertson; Jean-Christophe Bourdon; Neil Perkins; Frances Fuller-Pace; David W Meek
Journal:  Cell Cycle       Date:  2010-10-04       Impact factor: 4.534

7.  Seeking unique and common biological themes in multiple gene lists or datasets: pathway pattern extraction pipeline for pathway-level comparative analysis.

Authors:  Ming Yi; Uma Mudunuri; Anney Che; Robert M Stephens
Journal:  BMC Bioinformatics       Date:  2009-06-29       Impact factor: 3.169

8.  Effects of the kava chalcone flavokawain A differ in bladder cancer cells with wild-type versus mutant p53.

Authors:  Yaxiong Tang; Anne R Simoneau; Jun Xie; Babbak Shahandeh; Xiaolin Zi
Journal:  Cancer Prev Res (Phila)       Date:  2008-11

Review 9.  Tumor suppressive functions of p53.

Authors:  Jack T Zilfou; Scott W Lowe
Journal:  Cold Spring Harb Perspect Biol       Date:  2009-11       Impact factor: 10.005

10.  Pro-proliferative FoxM1 is a target of p53-mediated repression.

Authors:  A M Barsotti; C Prives
Journal:  Oncogene       Date:  2009-09-14       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.